Clinical Trial Update: Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea

View source ↗

Summary

This clinical trial update announces a postmarketing surveillance study of tezepelumab (Tezspire) in Korea for severe asthma, with recruitment not yet started.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma

Drugs mentioned

• Tezspire (tezepelumab)

Snippet

Sponsor: AstraZeneca | Conditions: Severe Asthma | Status: NOT_YET_RECRUITING